Century Therapeutics, Inc. Stock Price, News & Analysis

Century Therapeutics (NASDAQ: IPSC) will have CEO Lalo Flores present at the 21^st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 10:15 AM ET. He will also participate in a panel discussing key features in NK Cellular Therapeutics on April 14, 2022, at 11:00 AM ET. A live webcast of the presentation will be available on the company’s website, with an archived replay for 30 days post-event. Century Therapeutics focuses on developing innovative iPSC-derived cell therapies aimed at treating hematologic and solid tumor cancers.

Century Therapeutics (NASDAQ: IPSC) announced that CEO Lalo Flores, Ph.D., will present at the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, 2022. The presentation will focus on the company's development of induced pluripotent stem cell (iPSC)-derived cell therapies aimed at treating cancer. A recording will be available on their website starting March 30 at 7:00 AM ET for 90 days. Century's innovative approach seeks to advance cancer care by leveraging adult stem cells and genetic engineering.

Century Therapeutics (NASDAQ: IPSC) reported Q4 and full-year 2021 results, ending with $358.8 million in cash, ensuring operations into 2025. A strategic collaboration with Bristol Myers Squibb includes a $100 million upfront payment and a $50 million equity investment. The company plans to submit an IND for CNTY-101 in mid-2022 and initiate the Phase 1 ELiPSE-1 trial for relapsed/refractory lymphoma. R&D expenses rose to $75.6 million, contributing to a net loss of $95.8 million for 2021. The company anticipates operating expenses between $155 million and $165 million for 2022.

Century Therapeutics (NASDAQ: IPSC) announced that its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 PM ET. A live webcast of the event will be accessible on Century's website and available for replay for 90 days. The company focuses on developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, aiming to address the limitations of traditional cell therapies and enhance patient access.

Bristol Myers Squibb (NYSE:BMY) reported Q4 revenues of $12.0 billion, an 8% increase driven by robust sales of Eliquis and immuno-oncology products. Full-year revenues reached $46.4 billion, up 9%. Q4 earnings per share (EPS) stood at $1.07 (GAAP) and $1.83 (non-GAAP), with annual EPS at $3.12 and $7.51 respectively. The company announced a $15 billion share repurchase authorization and provided 2022 guidance, predicting $47 billion in revenues. The outlook includes expected growth from new products and a reduction in operating expenses.

Bristol Myers Squibb (NYSE:BMY) has reported fourth quarter revenues of $12.0 billion, marking an 8% increase year-over-year, and full-year revenues of $46.4 billion. The fourth quarter earnings per share (EPS) stand at $1.07 (GAAP) and $1.83 (non-GAAP), with full-year EPS at $3.12 and $7.51 respectively, reflecting a 17% growth in non-GAAP EPS. The company has authorized a $15 billion share repurchase initiative and announced a $5 billion accelerated share repurchase agreement for Q1 2022. Guidance for 2022 includes projected revenues of approximately $47 billion.

Century Therapeutics (NASDAQ: IPSC) and Bristol Myers Squibb (NYSE: BMY) have formed a collaboration to develop iPSC-derived cell therapies for hematologic malignancies. Century will receive an upfront payment of $100M and a $50M equity investment, with a total of up to $3B in potential milestone payments and royalties. The initial projects focus on acute myeloid leukemia and multiple myeloma. Bristol Myers Squibb will lead clinical development, while Century retains co-promotion rights. This partnership aims to leverage expertise in oncology and enhance the chances of successful outcomes.

Century Therapeutics (NASDAQ: IPSC) and Bristol Myers Squibb (NYSE: BMY) have announced a collaboration to develop allogeneic cell therapies targeting hematologic malignancies and solid tumors. Century will receive $150M, including $100M upfront and a $50M equity investment. Additional payments could exceed $3B based on program milestones. The first two programs focus on acute myeloid leukemia and multiple myeloma, leveraging Century's innovative iPSC technology.

On January 4, 2022, Century Therapeutics (NASDAQ: IPSC) announced that its CEO, Lalo Flores, Ph.D., will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 PM ET. The event will cover the company's advancements in iPSC-derived cell therapies for cancer treatment. A live webcast will be available on the company’s website, with a replay accessible for 30 days afterward. Century Therapeutics focuses on harnessing stem cells to improve patient care in oncology.